Finally, they proved their hypothesis that THZ2 can inhibit the progression of osteosarcoma by targeting SE-associated genes such as MYC, STAT3, and HMOX1. These findings indicate that THZ2 has the potential to become a promising targeting drug for osteosarcoma treatment. The gene discussed is STAT3; the disease is osteosarcoma.